Navigation Links
Bausch + Lomb Completes the Acquisition of ISTA Pharmaceuticals
Date:6/6/2012

MADISON, N.J., June 6, 2012 /PRNewswire/ -- Bausch + Lomb, the global eye health company, announced today that it has completed its acquisition of ISTA Pharmaceuticals, Inc., a leading pharmaceutical company.  The addition of ISTA bolsters Bausch + Lomb's product portfolio and pipeline, increasing the company's therapeutic offerings for physicians and their patients and creating opportunity for future growth. 

"This combination is a big step for Bausch + Lomb and an exciting development for eye health.  Together, we are building a high-performance company that can deliver even more benefits for the patients and customers we serve," said Brent Saunders, president and chief executive officer, Bausch + Lomb. "ISTA's business complements our own very well, and we are excited about the opportunities this transaction creates." 

ISTA's four prescription products, BROMDAY™, BEPREVE®, ISTALOL®, and VITRASE®, will complement Bausch + Lomb's existing prescription ophthalmology products, including Lotemax® and Besivance®, and branded OTC eye vitamins PreserVision® and Ocuvite®. Bausch + Lomb's pharmaceutical pipeline now has nearly double the number of mid-to late-stage innovations. The newly combined pipeline includes PROLENSA™, T-PRED™, BEPOMAX™ and BEPOSONE™, ISTA's candidates to treat ocular inflammation and pain and allergy-related nasal conditions, and Bausch + Lomb's pharmaceutical innovations, including the first of a new class of ocular anti-inflammatory agents as well as a promising approach to reducing intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension.

"The addition of ISTA creates exciting new opportunities for Bausch + Lomb's rapidly growing pharmaceutical business," said Daniel M. Wechsler, executive vice president and president, B
'/>"/>

SOURCE Bausch + Lomb
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux
2. Bausch + Lomb and Technolas™ Perfect Vision Introduce VICTUS™ Femtosecond Laser Platform at 2011 ESCRS Meeting
3. Bausch + Lomb Names John Barr Global President Surgical
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
10. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
11. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 28, 2015 ... therapeutics for the treatment of cancer, today announced the ... the U.S. Securities and Exchange Commission (SEC) relating to ... The number of shares to be offered and the ... determined. CytomX intends to list its common stock under ...
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on China,s ... Tobramycin is a traditional antibiotic whose eye drop ... the treatment of potential infection or inflammation caused by ... China are able to produce tobramycin, among ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Developed by Pharmacia & ... receptor agonist which effectively reduces intraocular pressure. As ... latanoprost (under the trade name of Xalatan) entered ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Tobramycin Market, 2015-2019 2China Latanoprost Market Investigation Report 2015-2019 2
(Date:8/29/2015)... ... August 30, 2015 , ... Rio Salado College ... as the college’s Vice President of Strategic Initiatives and Information Services. O’Shea, who has ... the college expand its reach and impact through innovative technologies and strategies. , “I ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... On Saturday, ... Mesothelioma Applied Research Foundation (Meso Foundation) will present an educational program titled ... 7:00 PM and lasts through 9:30 PM (doors open at 6:45pm) at Calvary United ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... may extend and improve the lives of patients, according to a newly published ... here to read the full article. , The authors of the new ...
(Date:8/29/2015)... ... August 29, 2015 , ... Next weekend is Labor ... (which astronomically, officially ends on September 22nd this year). For IT security personnel, it ... linger on which could prove far more costly than a simple headache. , Joe ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain have ... soft tissue manipulation. Platelet rich plasma injections also have mixed results. Building ... treatment outcomes. This localized treatment seems to address the symptoms and does ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
... ANGELES (May 5, 2010) High doses of antioxidant ... genetic abnormalities in cells, which may predispose supplement-takers to developing ... Institute. The study, led by Eduardo Marbn, ... online today in the medical journal Stem Cells . ...
... ... launches their professional organization business specializing in all areas of the home. ... (PRWEB) ... market this month. The company’s mission is to create fabulous homes through ...
... stroke , TUESDAY, May 4 (HealthDay News) -- Being ... attack or stroke in men older than 45, a new ... ages 45 to 69, who enrolled in the California Men,s ... followed until Dec. 31, 2007. , During the follow-up, there ...
... experts say , TUESDAY, May 4 (HealthDay News) -- While rates ... the United States, a new study finds that among young, white ... of lower stomach cancer is infection with the bacteria Helicobacter ... by acid reflux. Most stomach cancers are found in those aged ...
... works in different fashion than the current widely accepted ... of the drugparticularly in people with cancer and diseases ... (LAM). The results of this study, led ... Diseases Institute, are published in the May 5 edition ...
... A medication most often used to treat heart arrhythmias also ... type of muscular dystrophy in adults. The findings about ... were published May 4 in the journal Neurology , ... there is no drug approved to treat myotonic dystrophy, an ...
Cached Medicine News:Health News:High doses of antioxidant supplements induce stem cell genetic abnormalities 2Health News:Stomach Cancer on the Rise Among Young, White Adults 2Health News:Stomach Cancer on the Rise Among Young, White Adults 3Health News:Popular diabetes drug works differently than thought 2Health News:Heart drug effective for treating symptom of muscular dystrophy 2Health News:Heart drug effective for treating symptom of muscular dystrophy 3
10 L, Bulk Recommended for 2, 5 and 10 L pipettes....
10 L, Bulk Recommended for 5 & 10 L pipettes. Ideal for pipetting into long, narrow tubes or deep well plates....
This extended 10 ul combats contamination by keeping your pipettor out of 1.5 ul and 2.0 ul tubes. Utilizes MicroPoint design and 2 ul reference mark....
... The MonoPrep LBP Processor is a primary ... specimen collection, accessioning, processing, sampling, and slide ... data management. The MonoPrep LBP Processor produces ... from a broad range of cytology specimen ...
Medicine Products: